NURIX THERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid
NURIX THERAPEUTICS, INC. (NRIX) reported Capital Expenditures Incurred but Not yet Paid of $314.00 thousand for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-05-31 was -$1.39M.
- NURIX THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-02-28 was $1.70M, a 42.22% increase year-over-year.
- NURIX THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-11-30 was -$937.00K, a 180.78% decline year-over-year.
- NURIX THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-08-31 was $1.04M.
- NURIX THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $1.18M, a 28.00% decline from fiscal 2024.
- NURIX THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $1.64M, a 159.97% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $632.00K, a 53.97% decline from fiscal 2022.
- NURIX THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $1.37M, a 45.19% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-05-31 | -$1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $314.00K 10-Q · filed 2026-07-09 | -$623.00K derived: sum of 3 quarters · filed 2026-07-09 | $415.00K derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $1.70M 10-Q · filed 2026-04-08 | $764.00K derived: sum of 2 quarters · filed 2026-04-08 | $1.80M derived: sum of 3 quarters · filed 2026-04-08 | $1.69M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | -$937.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $101.00K derived: sum of 2 quarters · filed 2026-01-28 | -$13.00K derived: sum of 3 quarters · filed 2026-07-09 | $1.18M 10-K · filed 2026-01-28 |
| 2025-08-31 | $1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $924.00K derived: sum of 2 quarters · filed 2026-07-09 | $2.12M 10-Q · filed 2025-10-09 | $3.28M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | -$114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $1.08M 10-Q · filed 2026-07-09 | $2.24M derived: sum of 3 quarters · filed 2026-07-09 | $793.00K derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $1.20M 10-Q · filed 2026-04-08 | $2.36M derived: sum of 2 quarters · filed 2026-04-08 | $907.00K derived: sum of 3 quarters · filed 2026-04-08 | $1.98M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$289.00K derived: sum of 2 quarters · filed 2026-01-28 | $788.00K derived: sum of 3 quarters · filed 2026-01-28 | $1.64M 10-K · filed 2026-01-28 |
| 2024-08-31 | -$1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | -$372.00K derived: sum of 2 quarters · filed 2025-10-09 | $483.00K 10-Q · filed 2025-10-09 | $61.00K derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | $1.93M 10-Q · filed 2025-07-09 | $1.51M derived: sum of 3 quarters · filed 2026-01-28 | -$481.00K derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | $855.00K 10-Q · filed 2025-04-08 | $433.00K derived: sum of 2 quarters · filed 2026-01-28 | -$1.56M derived: sum of 3 quarters · filed 2026-01-28 | $53.00K derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | -$422.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$2.41M derived: sum of 2 quarters · filed 2026-01-28 | -$802.00K derived: sum of 3 quarters · filed 2026-01-28 | $632.00K 10-K · filed 2026-01-28 |
| 2023-08-31 | -$1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | -$380.00K derived: sum of 2 quarters · filed 2024-10-11 | $1.05M 10-Q · filed 2024-10-11 | $701.00K derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | $3.04M 10-Q · filed 2024-07-11 | $2.69M derived: sum of 3 quarters · filed 2025-01-28 | $1.73M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | $1.43M 10-Q · filed 2024-04-10 | $1.08M derived: sum of 2 quarters · filed 2025-01-28 | $114.00K derived: sum of 3 quarters · filed 2025-01-28 | $600.00K derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | -$353.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | -$1.32M derived: sum of 2 quarters · filed 2025-01-28 | -$834.00K derived: sum of 3 quarters · filed 2025-01-28 | $1.37M 10-K · filed 2025-01-28 |
| 2022-08-31 | -$967.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | -$481.00K derived: sum of 2 quarters · filed 2023-10-12 | $1.73M 10-Q · filed 2023-10-12 | $3.39M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | $486.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | $2.69M 10-Q · filed 2023-07-13 | $4.36M derived: sum of 3 quarters · filed 2023-07-13 | $4.59M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | $2.21M 10-Q · filed 2023-04-13 | $3.87M derived: sum of 2 quarters · filed 2023-04-13 | $4.11M derived: sum of 3 quarters · filed 2023-04-13 | $4.04M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $1.90M derived: sum of 2 quarters · filed 2023-02-09 | $1.84M derived: sum of 3 quarters · filed 2023-02-09 | $2.50M 10-K · filed 2023-02-09 |
| 2021-08-31 | $232.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | $171.00K derived: sum of 2 quarters · filed 2022-10-06 | $839.00K 10-Q · filed 2022-10-06 | $869.00K derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | -$61.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $607.00K 10-Q · filed 2022-07-07 | $637.00K derived: sum of 3 quarters · filed 2022-07-07 | $260.00K derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | $668.00K 10-Q · filed 2022-04-08 | $698.00K derived: sum of 2 quarters · filed 2022-04-08 | $321.00K derived: sum of 3 quarters · filed 2022-04-08 | $1.02M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | -$347.00K derived: sum of 2 quarters · filed 2022-01-28 | $349.00K derived: sum of 3 quarters · filed 2022-01-28 | $580.00K 10-K · filed 2022-01-28 |
| 2020-08-31 | -$377.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | $319.00K derived: sum of 2 quarters · filed 2021-10-14 | $550.00K 10-Q · filed 2021-10-14 | $627.00K derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | $696.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-13 | $927.00K 10-Q · filed 2021-07-13 | $1.00M derived: sum of 3 quarters · filed 2022-01-28 | |
| 2020-02-29 | $231.00K 10-Q · filed 2021-04-13 | $308.00K derived: sum of 2 quarters · filed 2022-01-28 | ||
| 2019-11-30 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $152.00K 10-K · filed 2022-01-28 | ||
| 2019-08-31 | $75.00K 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |